Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

Figures & data

Table 1. Patient demographics and clinical baseline characteristics.

Baseline characteristic		n (%)
Age, years	Median	49
	Range	3–71
Gender	Male	15 (48.4)
	Female	16 (51.6)
ECOG PS	0	7 (22.6)
	1	18 (58.1)
	2	6 (19.4)
Histological subtype	Leiomyosarcoma	10 (32.3)
	Liposarcoma	4 (12.9)
	Rhabdomyosarcoma	2 (6.5)
	Fibrosarcoma	2 (6.5)
	Ewing's sarcoma	2 (6.5)
	Undifferentiated sarcoma	2 (6.5)
	Osteosarcoma	2 (6.5)
	Angiosarcoma	2 (6.5)
	Fusocellular sarcoma	1 (3.2)
	Aggressive fibroma	1 (3.2)
	Malignant fibrous histiocytoma	1 (3.2)
	Sarcoma of the prostate	1 (3.2)
	Malignant neurinoma	1 (3.2)
Primary site	Abdominal cavity/retroperitoneum	14 (45.2)
	Extremity	7 (22.6)
	Pelvic cavity	7 (22.6)
	Trunk	3 (9.7)
Organ involvement	Lung	18 (58.1)
	Bone	8 (25.8)
	Liver	3 (9.7)
	Kidney	2 (6.5)
	Pancreas	1 (3.2)
Local therapy history	Surgery	26 (83.9)
	Interventional therapy	6 (19.4)
	Ablation	4 (12.9)
	Interventional therapy + Ablation	14 (45.2)
	None	7 (22.6)
Number of prior chemotherapy lines	0	4 (12.9)
	1	8 (25.8)
	2	10 (32.3)
	≥3	9 (29.0)
Agents used in prior regimen(s)	Doxorubicin/Epirubicin	23 (74.2)
	Cisplatin	23 (74.2)
	Ifosfamide	10 (32.3)
	Gemcitabine	4 (12.9)
	Paclitaxel	5 (16.1)
	Methotrexate	4 (12.9)

ECOG PS, Eastern Cooperative Oncology Group performance status.

Table 2. Baseline characteristic and clinical efficacy of 8 patients who achieved partial response.

		Sum of maximum diameter (cm)
Target lesion	Histological subtype	Before	After	Tumor shrinkage	Duration of response (months)
Lower limbs	Aggressive fibroma	8.2	4.3	47.56%	16.36
Lower limbs	Angiosarcoma	2.2	1.2	45.45%	15.93
Pelvic cavity	Leiomyosarcoma	5.5	3.2	41.82%	8.61
Liver	Undifferentiated sarcoma	6.4	4.2	34.38%	8.15
Lung	Ewing's sarcoma	5.2	2.5	51.92%	8.14
Lower limbs	Rhabdomyosarcoma	3.4	2.2	35.29%	5.55
Pelvic cavity	Leiomyosarcoma	4.3	2.1	51.16%	4.47
Lower limbs	Leiomyosarcoma	5.3	3.8	28.30%	4.24

Figure 1. The image data of one patient with lung metastatic sarcoma who achieved partial response one month following apatinib treatment.

Figure 2. Kaplan-Meier estimates of progression free survival and overall survival for all patients.

Figure 3. Kaplan-Meier estimates of progression free survival and overall survival for patients with leiomyosarcoma versus other histological subtypes.

Table 3. Adverse events.

	n (%)
Adverse event	All grade	Grade 1	Grade 2	Grade 3	Grade 4
Fatigue	17 (54.8)	9 (29.0)	8 (25.8)	0 (0)	0 (0)
Hypertension	14 (45.2)	9 (29.0)	3 (9.7)	2 (6.5)	0 (0)
Hand foot skin reaction	12 (38.7)	8 (25.8)	2 (6.5)	2 (6.5)	0 (0)
Nausea	12 (38.7)	9 (29.0)	3 (9.7)	0 (0)	0 (0)
Diarrhea	9 (29.0)	6 (19.4)	2 (6.5)	1 (3.2)	0 (0)
Proteinuria	5 (16.1)	3 (9.7)	2 (6.5)	0 (0)	0 (0)
Vomiting	3 (9.7)	2 (6.5)	1 (3.2)	0 (0)	0 (0)
Hematotoxicity	2 (6.5)	1 (3.2)	1 (3.2)	0 (0)	0 (0)
Headache	1 (3.2)	1 (3.2)	0 (0)	0 (0)	0 (0)
Tongue swelling	1 (3.2)	0 (0)	1 (3.2)	0 (0)	0 (0)